TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03788525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced recreational screen time
Description: Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed recreational screen time
Description: Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
Study: NCT01215409

Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: 5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
Study: NCT03289156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arousal Reappraisal
Description: Brief readings educating about the stress response and usefulness of arousal reappraisal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arousal Reappraisal
Description: Brief readings educating about the stress response and usefulness of arousal reappraisal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
Study: NCT04023409

Intervention type: OTHER
Intervention: NA: no intervention
Description: NA: no intervention
Study: NCT00876200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.
Study: NCT01556009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib
Description: 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid %20 topical solution
Description: 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
Study: NCT04734964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Exercise training session for 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Exercise training session for 45 minutes.
Study: NCT02631629

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified foods
Description: The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified foods
Description: The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified foods
Description: The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified foods
Description: The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
Study: NCT04033445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive guselkumab IV or SC.
Study: NCT03897088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PART 1: Double-blind Placebo-controlled
Description: all eligible subjects will receive either tildrakizumab or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PART 1: Double-blind Placebo-controlled
Description: all eligible subjects will receive either tildrakizumab or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PART 2: Double-blind Active Treatment Extension
Description: subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
Study: NCT03348943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Right hemiparesis, right upper limb.
Description: Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right hemiparesis, left upper limb
Description: Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Left hemiparesis, left upper limb
Description: Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Left hemiparesis, right upper limb
Description: Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
Study: NCT03784664

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: arterial blood sample with puncture of the radial artery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Veinous blood gas
Description: veinous blood sample using peripheral venepuncture
Study: NCT02415023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib+paclitaxel
Description: 28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
Study: NCT03787680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg by mouth twice a day for days 1-28 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg by mouth twice a day for days 1-28 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: 160 mg by mouth daily for days 1-7 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: 160 mg by mouth daily for days 1-7 of a 28-day cycle.
Study: NCT04069637

Intervention type: COMBINATION_PRODUCT
Intervention: Growth-sparing instrumentation and titanium levels
Description: Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
Study: NCT02192346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.4 mg/kg α-TEA
Description: Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0 mg/kg α-TEA
Description: Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.6 mg/kg α-TEA
Description: Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg/kg α-TEA
Description: Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19.2 mg/kg α-TEA
Description: Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 22.3 mg/kg α-TEA
Description: Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 26.8 mg/kg α-TEA
Description: Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
Study: NCT03033420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
Description: A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
Study: NCT01283919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole Sodium
Description: Pantoprazole Sodium DR Tablets 40 mg
Study: NCT04648358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone combined with bupivacaine
Description: The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
Study: NCT00556049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously on days 1 and 8 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Orally on days 1-14 of each 21-day treatment cycle
Study: NCT04527809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-active
Description: One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-sham
Description: One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
Study: NCT05515926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial manipulation group, or cranial osteopathic techniques (OMM)
Description: Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
Study: NCT00257712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH9507 human growth hormone releasing hormone (GHRH)
Description: 1mg subcutaneous injection given daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TH9507 human growth hormone releasing hormone (GHRH)
Description: 1mg subcutaneous injection given daily for 20 weeks
Study: NCT00264797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (OROS-MPH)
Description: Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate (OROS-MPH) - Placebo
Description: Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
Study: NCT01447563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulfate
Description: subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
Study: NCT02845895

Intervention type: OTHER
Intervention: Caregiver dedicated
Description: Organization of nutrition screening with the help of a caregiver

Intervention type: OTHER
Intervention: Classic strategy
Description: Classic organization with the training of the department team
Study: NCT03249584

Intervention type: DEVICE
Group type: OTHER
Intervention: OsteoCool™ RF Ablation
Description: The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
Study: NCT04180007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
Study: NCT00820625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation
Description: common pulmonary vein isolation procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation with additional ablation of fragmented potentials
Description: common pulmonary vein isolation with additional but also common ablation of fragmented potentials
Study: NCT02771548

Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Study: NCT02720510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: Revlimid was used with dexamethasone to treat patients with multiple myeloma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: Revlimid was used with dexamethasone to treat patients with multiple myeloma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone was a steroid used to treat patients with multiple myeloma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone was a steroid used to treat patients with multiple myeloma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farydak
Description: FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
Study: NCT01669538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00406913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mupirocin ointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC sterilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC sterilization
Study: NCT03229005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: during surgery soft tissues will be measured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant insertion
Description: during surgery soft tissues will be measured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: during surgery soft tissues will be measured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant insertion
Description: during surgery soft tissues will be measured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operculectomy
Description: during second surgery soft tissues will be measured again

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prosthetic rehabilitation
Description: after three months implants will be loaded with screw retained crown
Study: NCT02129348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02684578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03893539

Intervention type: DEVICE
Group type: OTHER
Intervention: Ion Endoluminal System™
Description: The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
Study: NCT00488865

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular Filter Device
Description: Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
Study: NCT03043924

Intervention type: DRUG
Group type: OTHER
Intervention: Cyproterone Acetate + estradiol
Description: PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily

Intervention type: DRUG
Group type: OTHER
Intervention: Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet
Description: Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
Study: NCT00790959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASA!
Description: A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers.
Study: NCT04211493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: whole-body-workout
Description: 20 minutes whole-body-workout

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: whole-body-workout
Description: 20 minutes whole-body-workout

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: Electromyostimulation-intensity 5 (muscle stimulation)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMS-Placebo
Description: Electromyostimulation-intensity 1 (no muscle stimulation)